arrow
T

Takahiro Kimura

the jikei university hospital
H指数:37
被引数:6,538

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer

转移性激素敏感性前列腺癌中 Gleason 图案 5 对双药与三药疗法临床影响的比较

2026-09-290
OAAI
Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study

机器学习集成可解释人工智能在预测恩福妥单抗维多汀在尿路上皮癌毒性中的作用:一项探索性研究

2026-09-160
PRE
Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy

前列腺中分化腺癌和导管内癌在诊断性活检中对接受ARPI为基础治疗的前列腺癌患者的预后影响

2026-08-010
PRE
Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'

作者回复:“达罗鲁胺三联疗法期间发热性中性粒细胞减少症风险和初级G-CSF预防的贝叶斯解释”

2026-08-010
PRE
Pathological Predictors of Limited Salvage Radiotherapy Efficacy After Radical Prostatectomy: Central Review of JCOG0401

局限性挽救性放疗在根治性前列腺切除术后疗效的病理学预测因素:JCOG0401研究的中心回顾

Cancers
IF4.4
2026-06-080
OAAI
Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features

前列腺癌诊断时循环神经内分泌肿瘤标志物的评估:一项针对具有神经内分泌特征的前列腺癌的研究

2026-04-170
PRE
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

良性前列腺增生手术后偶发前列腺癌的风险因素:一项系统评价和荟萃分析

2026-03-230
PRE
Prognostic impact of intraductal carcinoma of the prostate and PTEN loss in metastatic castration-sensitive prostate cancer treated with androgen receptor pathway inhibitors

前列腺导管内癌和PTEN缺失对接受雄激素受体通路抑制剂治疗的转移性去势敏感性前列腺癌的预后影响

2026-01-010
PRE
Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

肌层浸润性膀胱癌三联疗法的预后因素:一项系统评价和Meta分析

2025-12-180
OAAI
Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

新辅助化疗在肌层浸润性膀胱癌三模式治疗前的应用:系统评价与Meta分析

2025-12-040
OAAI
Rapidly progressive and fatal drug-induced interstitial pneumonitis after three cycles of enfortumab vedotin plus pembrolizumab treatment for metastatic urothelial carcinoma: a case report

快速进展且致命的药物性间质性肺炎,发生于接受恩沃利单抗 vedotin 联合帕博利珠单抗治疗转移性尿路上皮癌3个周期后:病例报告

2025-12-010
PRE
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

早期调整一线雄激素受体信号抑制剂对转移性激素敏感性前列腺癌生存结局的影响

2025-11-060
PRE
Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study

恩普替尼(enfortumab vedotin)联合帕博利珠单抗(pembrolizumab)在局部晚期或转移性尿路上皮癌中的安全性特征:一项多中心日本队列研究

2025-11-010
PRE
Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

PSMA靶向放射性配体疗法在转移性去势抵抗性前列腺癌中的预后因素:一项系统综述和荟萃分析

2025-10-080
OA